Chemical raw materials become the focus of fine chemicals

The chemical raw material is a ruler measuring the fine chemical industry to what extent. China has long been based on’ uneducated’ image on chemical raw materials, for the production is extensive, export allocation and almost no innovation. China chemical raw materials taking this extensive growth path, it is difficult to maintain sustained and rapid growth, therefore, it will become an important issue in the fine chemicals year.

In the new year, the export of chemical raw materials are blocked, low-carbon economic development effort, increased competition and other traditional areas of multiple challenges. In recent years, Chinese people, the production cost and other advantages are attracting multinational pharmaceutical giant, the raw material drug production to China. Chinese enterprises are facing more pressure.

China is the world's largest producer of bulk drugs and capable of producing more than 1500 kinds of bulk drugs. The varieties are greatest in the world. Meanwhile, China is the world's largest exporter of chemical raw materials, bulk drugs exports of domestic production accounted for nearly half. Since 2001, China's API exports an average annual compound growth rate of more than 20%. In 2008, total export volume of China's API is $ 23.894 billion, an increase of 22.19%. Which exports reached $ 17.58 billion, an increase of 29.59%, and profit increase of about 50%. Export of bulk drugs industry pulling effect is obvious.

But since 2009, API is the industry's first negative growth statistics make this area known as the export haven filled with the waves. 1 November last year, China's total export of chemical raw materials for the $ 14.87 billion, down by 7.35%. In major export markets, exports to Asia, 64.8 million U.S. dollars, down 3.24%; Europe 42.5 billion U.S. dollars, down 11.86%; North America for $ 2.27 billion, down 11.83%. Over the past five years, China is the first negative growth in exports of chemical raw materials octylferrocene. In fact, do not fly to export as a safe haven is inevitable. In the financial turmoil sweeping the world situation, the deterioration of the international economic environment inevitably affect the export of chemical raw materials. Such as Africa, Nigeria, half due to exchange rate depreciation, local buyers can schedule payments to Chinese enterprises has caused tremendous losses. India, Europe, the supply of medicines in Africa decreased significantly, resulting in a further decline in demand for bulk drugs, lower prices. Another reason for the decline in exports increased competition. India is China's raw materials, pharmaceutical intermediates and fine chemical products, the main export destination, accounting for China's total exports of pharmaceutical products 16.5%, after the United States. But India is also a Chinese chemical raw materials the company's competitors. Sino-Indian trade in the pharmaceutical and chemical class, there are some long-term paradox: on the one hand, the Indian pharmaceutical companies need to import the raw material cost advantage of Chinese medicine with intermediate; the other hand, India has worried about the rapid development of Chinese chemical raw materials industry, China's raw material Indian drug will occupy most of the market. Therefore, under the ideological influence of trade protection, reduction and boycott Chinese imports of pharmaceutical products to become the major forces in the Indian market. Within the past year, India twice on the production of penicillin industrial salt from China initiated anti-dumping investigations. This is the result of chemical raw materials for Chinese exports to India, an important reason for the decline. Moreover, this phenomenon also will continue.

Although countries in the UN Climate Change Conference in Copenhagen reached only on a non-legally binding agreement, but by improving energy efficiency and reduce carbon emissions to combat climate change has become the consensus of the world. In this context, the "three low-mode" (low power consumption, low emissions) and ‘low-carbon economy’, ‘low-carbon development’ and a series of new concepts and new policy will come into being. Released in China to determine the action to control greenhouse gas emissions targets, only 40% to 45% emission reduction target, also referred to ‘speed up the construction industry is characterized by a low-carbon system.’ Thus, a ‘low carbon’ is characterized by the pharmaceutical manufacturing industry industrial system as described blueprint for future development are an important sum.

Pharmaceutical industry is one of China's heavy polluting industries. In 2003, China will pharmaceutical included in the list of heavily polluting industries. As the synthetic bulk drugs and bulk drugs production fermentation process produces the "three wastes" more. While vitamin C and penicillin both Chinese medicine raw materials sub-sectors included in the bulk limit the development of class projects.

Chemical raw materials industry "exports, the pollution left behind" feature has been the subject of criticism. Because of pollution, developed many years ago put the high pollution and low added value of the chemical raw materials industries to Third World countries. China is also in the globalization of the industrial division to undertake a number of high pollution, high energy consumption industries. Profits of the main export of chemical raw materials industry, described the Chinese pharmaceutical manufacturing industry in the most polluted industry - its export-oriented products, while consumption in other countries, China is carrying resource consumption and carbon emissions double the price.

All the signs indicate that the ‘low-carbon manufacturing,’ the pharmaceutical industry structural adjustment era has come, the Chinese chemical raw pharmaceutical companies how to achieve low-carbon has become an unavoidable issue.

Italian imitation of the latest CPA report, the global market of chemical raw materials in 2004 was 680 billion U.S. dollars, and by 2008 more than $ 90 billion, of which the global generic sales in 2008 reached $ 78 billion over the previous year growth of 4%. The reason why the world's promising generic drug market, because each innovation in drug development costs up to 30 million to 1.6 billion U.S. dollars, the market cycle to be 5 to 8 years, and R & D success rate of a million. Faced with such a high threshold to enter the person rare. To include generic drugs, including generic drugs to meet the needs of most diseases today, the price was only about 10% of innovative drugs. In addition, the world is facing pressure to reduce health costs of the original

Also makes generic drugs favored by. Currently the world are continuing to reduce medical costs, such as France are forced to cut prices 40% of the drugs, the United States in many therapeutic areas to reduce drug prices, many Chinese medicines has also been included in the price ceiling directory. All this makes the global pharmaceutical industry to find new more cost-competitive generic market.

Generic is China's traditional territory of chemical raw materials enterprises. China is a large country with generic drugs Musk R-1, in the past China has approved more for generic drugs. China's pharmaceutical enterprises are mainly based on the production of generic drugs, a large number of patented drug concentrations due, no doubt for the chemical raw materials business development opportunities. However, this opportunity is equal, Chinese enterprises welcome development opportunities at the same time, foreign companies have long coveted a long time for this opportunity. In particular, China's new medical reform will be implemented low-level, wide coverage of health insurance policy, the future market demand for quality and cheap generic drugs will become more urgent. Many multinational companies have chemical raw materials to China, the generics market as a key research goal. Foreign enterprises in the overall quality of generic drugs has obvious advantages, especially complex and difficult for generic drugs has technical advantages. In addition, they are thoroughly international pharmaceutical market research, access to medical resources, drug information quickly and efficiently for the generic drug patent expiration helps to grasp the market opportunities.

In contrast, although China is a big generics country, it is still not a really powerful country on generic drugs. Industry experts point out that the majority of Chinese chemical raw products are still in the extensive stage of imitation, such as in the processing and transformation. If Chinese enterprises want to seize opportunities in the development of generic drugs in China and make competition with foreign giants or even the world market, they must vigorously strengthen the quality of manufacturing technology management and technology innovation.